A Comparative Study of Aminosidine Sulfate, Meglomine Antimoniate, Combination of both and Glucantime in Murine Leishmaniasis Treatment of Cutaneous Leishmaniasis, Caused by Leishmania tropica, with Topical Application of Paromomycin 20% in BALB-c Mice

authors:

avatar Mohammad Shahidi Dadras 1 , * , avatar Afshin Mirzaei 2 , avatar Bahram Kazemi 3 , avatar Leyla Nabai 1 , avatar Ali Sharifian 1

Skin Research Center, Shohada Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
Faculty of Medicine, Rafsanjan University of Medical Science, Rafsanjan, Iran
Cellular and Molecular Biology Research Center, Faculty of Medicine, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
Iranian Journal of Pharmaceutical Research: Vol.6, issue 3; 209-215
published online: November 20, 2010
article type: Research Article
received: November 21, 2005
accepted: March 21, 2006
DOI: https://doi.org/10.22037/ijpr.2010.723

how to cite: Shahidi Dadras M, Mirzaei A, Kazemi B, Nabai L, Sharifian A. A Comparative Study of Aminosidine Sulfate, Meglomine Antimoniate, Combination of both and Glucantime in Murine Leishmaniasis Treatment of Cutaneous Leishmaniasis, Caused by Leishmania tropica, with Topical Application of Paromomycin 20% in BALB-c Mice. Iran J Pharm Res. 2007;6(3):e128334. https://doi.org/10.22037/ijpr.2010.723.

Abstract

The current treatment of choice for cutaneous leishmaniasis is either parenteral or intralesional antimonial compounds. Each of these treatments has its own downfalls which include toxic side effects with the parentral injection and pain at the site of injection with the intralesional injection. In recent years, there has been more focus on Paromomycin as an alternative drug; however, current data arose many controversies.

In this study, the efficacy of different therapeutic regimens including topical paromomycin 20%, topical gentamycin 0.5%, intralesional glucantime injections, topical paromomycin 20% combine with gentamycin 0.5%, and placebo were compared. The results showed that the topical application of paromomycin had better response, less recurrence. In conclusion, topical paromomycin 20% can be an appropriate substitute for intralesional injection of glucantime, but more studies are needed to support its efficacy in human cutaneous leishmaniasis.